MG1131 / GC Biopharma - LARVOL DELTA

Discovery and preclinical evaluation of novel peptide inhibitors targeting the TIGIT immune checkpoint (AACR 2026) - "Through computational affinity maturation, starting from the anti-TIGIT antibody MG1131, we identified a library of TIGIT-inhibitory peptides...Tumor growth dynamics, as well as the phenotype, cytokine profile and activation status of T cells in the tumor microgovernment, tumor-draining lymph nodes, and spleens will be assessed in the treated groups and compared with control groups. Collectively, this study introduces novel TIGIT-blocking peptides as promising candidates for cancer immunotherapy, offering a potential alternative or complementary approach to antibody-based immune checkpoint blockade."

IO biomarker • Preclinical • Oncology • CD4 • CD8 • IFNG • PVR • TIGIT

Structural and functional characterization of a monoclonal antibody blocking TIGIT. (PubMed, MAbs) - "MG1131 also increased T cell infiltration to the tumor site and inhibited tumor growth in mice. Collectively, these data indicate that MG1131 modulates the effector functions of T cells and NK cells positively and Treg cells negatively."

Journal • Hematological Malignancies • Immune Modulation • Inflammation • Multiple Myeloma • Oncology • IFNG • TIGIT